Bayer Other Long-Term Assets 2010-2024 | BAYRY

Bayer other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Bayer other long-term assets for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Bayer other long-term assets for 2023 were $0B, a NAN% decline from 2022.
  • Bayer other long-term assets for 2022 were $0B, a NAN% decline from 2021.
  • Bayer other long-term assets for 2021 were $0B, a NAN% decline from 2020.
Bayer Annual Other Long-Term Assets
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $2,492
2010 $2,207
2009 $2,439
Bayer Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $2,492
2011-09-30 $2,154
2011-06-30 $2,242
2011-03-31 $2,248
2010-12-31 $2,207
2010-09-30 $2,251
2010-06-30 $2,409
2010-03-31 $2,646
2009-12-31 $2,439
2009-09-30 $2,713
2009-06-30 $2,430
2009-03-31 $2,353
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $20.120B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $759.358B 78.65
Novo Nordisk (NVO) Denmark $387.095B 27.92
Johnson & Johnson (JNJ) United States $342.027B 13.87
AbbVie (ABBV) United States $309.550B 16.29
Merck (MRK) United States $251.066B 16.68
AstraZeneca (AZN) United Kingdom $207.774B 17.68
Novartis AG (NVS) Switzerland $202.520B 13.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $123.669B 11.20
Innoviva (INVA) United States $1.082B 9.00